January 04, 2021
Weil is advising Magellan Health, a Fortune 500 company and a leader in managing the fastest growing, most complex areas of health, including special populations, complete pharmacy benefits and other specialty areas of healthcare, in its $2.2 billion merger with Centene Corporation, a Fortune 50 company and leading multinational healthcare enterprise that provides fully integrated, high-quality, and cost-effective services to government-sponsored and commercial healthcare programs, focusing on under-insured and uninsured individuals. The transaction is expected to close in the second half of 2021, subject to customary closing conditions.
The Weil team advising Magellan Health is led by Mergers & Acquisitions partners Raymond Gietz and Jackie Cohen and includes Mergers & Acquisitions associates Rachel Shapiro, Chelsea Berry, Michael Block and Jason Klig. The team also includes Tax partner Helyn Goldstein; Tax counsel Eric Remijan; Tax associate Mary Sommers; Executive Compensation & Benefits partner Amy Rubin; Executive Compensation & Benefits associate Lauren Sawyer (Not Yet Admitted in New York); Public Company Advisory Group partner Adé Heyliger; Antitrust partner Steven Bernstein; Antitrust counsel Alexis Brown-Reilly and Rob Meyer; Antitrust associate Richard Flannery; Banking & Finance partner Danek Freeman; Banking & Finance associate H.T. Flanagan; Capital Markets partner Corey Chivers; Technology & IP Transactions partner Jeffrey Osterman; Technology & IP Transactions counsel Marisa Geiger; Technology & IP Transactions/Privacy associates Kane Wishart, Olivia Greer and Caleb Small; Regulatory Transactions counsel John O’Loughlin; Employment Litigation partner Nicholas Pappas and Employment Litigation associate Omar Abdel-Hamid (Not Yet Admitted in New York).